Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2264
+0.00040.18%
Post-market: 0.23060.0042+1.86%19:14 EDT
Volume:1.15M
Turnover:258.28K
Market Cap:9.29M
PE:-0.12
High:0.2345
Open:0.2230
Low:0.2191
Close:0.2260
52wk High:5.14
52wk Low:0.1980
Shares:41.03M
Float Shares:35.04M
Volume Ratio:1.73
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8303
EPS(LYR):-1.8303
ROE:-131.59%
ROA:-67.84%
PB:0.26
PE(LYR):-0.12

Loading ...

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Reuters
·
Jul 06

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

TIPRANKS
·
Jul 06

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 01

Vistagen Tumbles as Social Anxiety Drug Misses Main Goal in Late-stage Trial

Reuters
·
Jun 30

Vistagen Therapeutics Says Fasedienol Didn't Meet Primary Endpoint in Study

Dow Jones
·
Jun 30

Vistagen Says Fasedienol Misses Primary Endpoint in Palisade-4 Phase 3 Social Anxiety Trial

Reuters
·
Jun 30

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Plans to Meet with FDA on Registration Pathway for Fasedienol with Future Phase 3 Trial

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Fasedienol Did not Achieve Statistically Significant Improvement on Primary and Secondary Endpoints

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Post-hoc Analysis Shows Nominal Statistical Significance for Fasedienol in Very Severe Social Anxiety Subgroup

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Favorable Safety and Tolerability Data were Consistent with Previous Clinical Trials

THOMSON REUTERS
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Jun 30

VistaGen directors FitzPatrick, Curley to step down after 2026 annual meeting

Reuters
·
Jun 18

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

TIPRANKS
·
Jun 17

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

Benzinga
·
Jun 16

VistaGen FY26 net loss widens to $69.7 million; R&D expense rises to $55 million

Reuters
·
Jun 16

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jun 16

Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds

MT Newswires Live
·
Jun 10

Vistagen announces fasedienol achieves minimum patient exposures

TIPRANKS
·
Jun 09

Vistagen Achieves Minimum Ich Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 09